ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
ma420
|
159 |
41K |
3 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
159
|
41K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Proposed issue of securities - PAA
|
|
ma420
|
15 |
3.6K |
3 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
15
|
3.6K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Proposed issue of securities - PAA
|
|
ma420
|
15 |
3.6K |
17 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
15
|
3.6K
|
17
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
773K |
11 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
2.2K
|
773K
|
11
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
773K |
12 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
2.2K
|
773K
|
12
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
922 |
325K |
12 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
922
|
325K
|
12
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
922 |
325K |
9 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
922
|
325K
|
9
|
|
ASX - By Stock
|
COV |
Re:
Ann: Restricted securities to be released from escrow
|
|
ma420
|
3 |
1.3K |
1 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
3
|
1.3K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
773K |
9 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
2.2K
|
773K
|
9
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
773K |
13 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
2.2K
|
773K
|
13
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
922 |
325K |
2 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
922
|
325K
|
2
|
|
ASX - By Stock
|
BOT |
Re:
Ann: FDA Approves Sofdra
|
|
ma420
|
554 |
203K |
4 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
554
|
203K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
ma420
|
146 |
44K |
12 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
146
|
44K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
ma420
|
132 |
48K |
23 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
132
|
48K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
ma420
|
159 |
41K |
12 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
41K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
ma420
|
159 |
41K |
20 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
41K
|
20
|
|
ASX - By Stock
|
RAC |
Re:
Ann: FDA RPD Designation Granted for RC220 Bisantrene
|
|
ma420
|
80 |
26K |
6 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
80
|
26K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix to present at Melbourne Twilight Investor Briefing
|
|
ma420
|
95 |
40K |
5 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
95
|
40K
|
5
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
558 |
224K |
11 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
558
|
224K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
ma420
|
230 |
110K |
7 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
230
|
110K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
ma420
|
230 |
110K |
22 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
230
|
110K
|
22
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
ma420
|
230 |
110K |
20 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
230
|
110K
|
20
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
558 |
224K |
2 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
558
|
224K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
558 |
224K |
2 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
558
|
224K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
ma420
|
230 |
110K |
4 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
230
|
110K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
ma420
|
230 |
110K |
16 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
230
|
110K
|
16
|
|
ASX - By Stock
|
DXB |
Re:
Banter and general comments
|
|
ma420
|
81 |
34K |
1 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
81
|
34K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
558 |
224K |
3 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
558
|
224K
|
3
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
214 |
121K |
15 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
214
|
121K
|
15
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
4.0M |
12 |
14/06/24 |
14/06/24 |
General
|
11K
|
4.0M
|
12
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
4.0M |
2 |
14/06/24 |
14/06/24 |
General
|
11K
|
4.0M
|
2
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
214 |
121K |
22 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
214
|
121K
|
22
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ma420
|
2.3K |
780K |
8 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
2.3K
|
780K
|
8
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
4.0M |
25 |
14/06/24 |
14/06/24 |
General
|
11K
|
4.0M
|
25
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
558 |
224K |
6 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
558
|
224K
|
6
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity Confirms No Supply Disruptions for Clinical Trials
|
|
ma420
|
11 |
4.7K |
1 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
11
|
4.7K
|
1
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
214 |
121K |
18 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
214
|
121K
|
18
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
558 |
224K |
19 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
558
|
224K
|
19
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ma420
|
2.3K |
780K |
2 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
2.3K
|
780K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ma420
|
2.3K |
780K |
0 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
2.3K
|
780K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
|
|
ma420
|
110 |
37K |
0 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
110
|
37K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
|
|
ma420
|
110 |
37K |
1 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
110
|
37K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
|
|
ma420
|
110 |
37K |
0 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
110
|
37K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model
|
|
ma420
|
82 |
26K |
1 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
82
|
26K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ma420
|
2.3K |
780K |
2 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
2.3K
|
780K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Application for quotation of securities - RAC
|
|
ma420
|
1 |
976 |
9 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
1
|
976
|
9
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model
|
|
ma420
|
82 |
26K |
14 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
82
|
26K
|
14
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
922 |
325K |
11 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
922
|
325K
|
11
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
ma420
|
22K |
7.7M |
3 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
22K
|
7.7M
|
3
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
62 |
26K |
1 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
62
|
26K
|
1
|
|